News

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Media Contact

Stephen Schultz
VP Investor Relations (U.S.)
T: 917-280-2424 / 401 500 6570
sschultz@gwpharm.com
 

Recent Press Releases

Dec 01, 2009
Porton Down, UK, 1 December 2009 - GW Pharmaceuticals plc (AIM: GWP) is pleased to announce the appointment, with immediate effect, of Piper Jaffray Ltd as Nominated Advisor and broker to the Compan
Nov 25, 2009
Porton Down, UK, 25 November 2009: GW Pharmaceuticals plc (AIM: GWP), the developer and manufacturer of a range of new cannabinoid medicines, including Sativex®, announces its preliminary results fo
Nov 25, 2009
Porton Down, UK, 25 November 2009: GW Pharmaceuticals plc (GWP:AIM) announces that it has completed recruitment into its Sativex® Phase II/III cancer pain trial.
Nov 23, 2009
Porton Down, UK, 23 November 2009: GW Pharmaceuticals plc (GWP:AIM) announces that the results of a clinical study of Sativex® in the treatment of cancer pain have been published in the highly-regar
Sep 14, 2009
Home Office licenses research into medical uses of cannabis
Sep 10, 2009
GW Pharmaceuticals plc (AIM: GWP) announces that its Managing Director, Justin Gover, will be presenting at the Rodman and Renshaw Annual Global Investment Conference in New York on Thursday, September 10, 2009 at 3
Aug 06, 2009
GW Pharmaceuticals plc (GWP:AIM), the developer and manufacturer of a range of new cannabinoid medicines, including Sativex, today announces that it has signed an agreement with funds controlled by Great Point Partn
Jul 16, 2009
GW Pharmaceuticals plc (GWP:AIM) today announces that it has passed a Good Manufacturing Practice (GMP) inspection by the UK regulatory authority of its new in-house commercial manufacturing facility for Sativex, en
Jun 16, 2009
GW Pharmaceuticals plc (GWP:AIM) today announces that it has entered into an exclusive strategic alliance with Professor Mike Cawthorne and the Clore Laboratory, University of Buckingham, focusing on the research of
May 20, 2009
GW Pharmaceuticals plc (GWP:AIM) today announces that it has filed a regulatory submission for Sativex for the treatment of spasticity due to Multiple Sclerosis.

Pages